Abstract: The disclosure relates generally to molecules that specifically engage death receptor 5 (DR5), a member of the TNF receptor superfamily (TNFRSF). More specifically the disclosure relates to multivalent and multispecific molecules that bind at least DR5.
Type:
Grant
Filed:
August 5, 2021
Date of Patent:
May 7, 2024
Assignee:
Inhibrx, Inc.
Inventors:
John C. Timmer, Kyle S. Jones, Amir S. Razai, Abrahim Hussain, Katelyn M. Willis, Quinn Deveraux, Brendan P. Eckelman
Abstract: Provided herein are libraries containing synthetic polynucleotides that encode activatable binding polypeptides. Further provided herein are activatable binding polypeptides and polypeptide libraries containing such activatable binding polypeptides. Also provided herein are vectors, vector libraries, cells, kits, and methods of making and using activatable polypeptide libraries.
Abstract: The present disclosure provides improved compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.
Abstract: The invention relates to LAG-3 binding agents, in particular variable heavy chain (VH) sdAbs and bispecific agents that target both LAG-3 and PD-1, and the use of such binding agents in the treatment, prevention and detection of disease.
Type:
Grant
Filed:
February 18, 2019
Date of Patent:
April 9, 2024
Assignee:
CRESCENDO BIOLOGICS LIMITED
Inventors:
Carolyn Edwards, Angelica Sette, Isabelle Osuch, Yumin Teng, James Legg, David Escors Murugarren
Abstract: B-cell maturation antigen (BCMA) is expressed on malignant plasma cells. The present invention provides methods for treating multiple myeloma using bispecific antibodies (bsAbs) that bind to both BCMA and CD3 and activate T cells via the CD3 complex in the presence of BCMA-expressing tumor cells. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing BCMA.
Type:
Grant
Filed:
December 4, 2020
Date of Patent:
March 5, 2024
Assignee:
Regeneron Pharmaceuticals, Inc.
Inventors:
Israel Lowy, David Sternberg, Manish Sharma, Lieve Adriaens
Abstract: Provided herein are polynucleotides encoding chimeric antigen receptors (CARs) comprising a CD19 antigen binding domain that specifically binds to CD19 and is resistant to rituximab binding; and immune cells comprising these CD19-specific CARs, e.g., CAR-T cells. Also provided are methods of making and using these CD19-specific CARs, and immune cells comprising these CD19-specific CARs.
Type:
Grant
Filed:
April 24, 2020
Date of Patent:
February 13, 2024
Assignee:
ALLOGENE THERAPEUTICS, INC.
Inventors:
Thomas Charles Pertel, Barbra Johnson Sasu, Mark W. Leonard
Abstract: The invention features combination therapies using an IL-15-based superagonist complex and an antibody to effectively treat subjects with cancer and infectious diseases.
Type:
Grant
Filed:
December 9, 2022
Date of Patent:
February 6, 2024
Assignee:
Altor Bioscience, LLC
Inventors:
Bai Liu, Peter Rhode, Wenxin Xu, Hing C. Wong
Abstract: The present invention is directed toward monoclonal antibodies that bind to death receptor 4 and/or death receptor 5, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.
Type:
Grant
Filed:
February 2, 2021
Date of Patent:
February 6, 2024
Assignee:
GALAXY BIOTECH, LLC
Inventors:
Kyung Jin Kim, Hangil Park, Lihong Wang, Yi Ding, April Zhang, Maximiliano Vasquez
Abstract: The invention is directed to T cells and other cells that express chimeric NK-p30 receptors (“chimeric NKp30 T cells”), methods of making and using chimeric NKp30 T cells, and methods of using these chimeric NKp30 T cells, isolated populations thereof, and compositions comprising the same. In another aspect, said chimeric NKp30 T cells are further designed to express a functional non-TCR receptor. The disclosure also pertains to methods of making said chimeric NKp30 T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said chimeric NKp30 T cells, populations thereof, or compositions comprising the same.
Abstract: Described herein are anti-CD30L antibodies and pharmaceutical compositions for the treatment of autoimmune diseases and disorders such inflammatory bowel disease (IBD), including Crohn's Disease (CD) and ulcerative colitis (UC).
Type:
Grant
Filed:
August 26, 2022
Date of Patent:
January 9, 2024
Assignees:
PROMETHEUS BIOSCIENCES, INC., DR. FALK PHARMA GMBH
Inventors:
Jessie-Farah Fecteau, Mark Renshaw, Johan Fransson, Olivier Laurent, Burton Barnett
Abstract: Humanized antibodies, capable of specific binding to human CEACAM1 molecules containing human-to-murine back-mutations in non-CDR variable regions, and their encoding polynucleotide sequences are provided. Pharmaceutical compositions comprising these antibodies as well as methods of their use in treating and diagnosing cancer and other conditions are also provided.
Type:
Grant
Filed:
May 18, 2020
Date of Patent:
January 9, 2024
Assignee:
FAMEWAVE LTD.
Inventors:
Tehila Ben-Moshe, Yair Sapir, Ilana Mandel, Gal Markel, Jacob Schachter, Rona Ortenberg, Francis Joseph Carr, Robert George E. Holgate, Timothy David Jones
Abstract: Provided are antibodies that bind to human CD137 or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, and for the treatment of cancer.
Type:
Grant
Filed:
August 21, 2018
Date of Patent:
January 2, 2024
Assignee:
Adagene Inc.
Inventors:
Peter Peizhi Luo, Fangyong Du, Guizhong Liu, Yan Li, Jun Chen, Xiaohong She, Peter Cheung
Abstract: The present invention relates to antagonistic TNFR2 polypeptides, such as antibodies and antigen-binding fragments thereof, and the use of these polypeptides to inhibit the proliferation of regulatory T cells (T-regs) and/or expand T effector cell populations or function. For example, antibodies of the invention include antagonistic TNFR2 antibodies and antigen-binding fragments thereof, and can be used to suppress the T-reg-mediated deactivation of tumor reactive T-lymphocytes, as well as to treat a wide variety of cancers and infectious diseases.
Abstract: The present invention relates to targeted IL-12 heterodimeric Fc fusion proteins, where the fusion proteins bind to human PD-1 or human PD-L1.
Type:
Grant
Filed:
October 2, 2020
Date of Patent:
December 26, 2023
Assignee:
Xencor, Inc.
Inventors:
Matthew Bernett, John R. Desjarlais, Rajat Varma, Ke Liu, Rumana Rashid, Nargess Hassanzadeh-Kiabi, Michael Hedvat
Abstract: This invention relates to binding molecules that bind specifically to TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) and cadherin-17 (CDH17) and their use in medicine, pharmaceutical compositions comprising the same, and methods of using the same as agents for treatment and/or prevention of cancer.
Type:
Grant
Filed:
October 30, 2020
Date of Patent:
December 26, 2023
Assignee:
Boehringer Ingelheim International GmbH
Inventors:
Klaus-Peter Kuenkele, Timothy Fenn, Juan Manuel Garcia-Martinez, Jason Ho, Christian Koessl, Saurabh Sen, Vladimir Voynov, Andreas Wernitznig
Abstract: Multi-specific binding proteins that bind a tumor associated antigen, the NKG2D receptor, and CD 16 are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.
Type:
Grant
Filed:
February 8, 2018
Date of Patent:
December 5, 2023
Assignee:
Dragonfly Therapeutics, Inc.
Inventors:
Gregory P. Chang, Ann F. Cheung, William Haney, Asya Grinberg
Abstract: Provided herein are cells, e.g., T cells expressing artificial cell death polypeptides that cause death of a cell, e.g., cells (e.g., T lymphocytes) expressing the cell death polypeptide, when the cell death polypeptide is multimerized or dimerized. Also provided herein is use of such cells, e.g., T lymphocytes, to treat diseases such as cancer.
Type:
Grant
Filed:
March 5, 2021
Date of Patent:
November 7, 2023
Assignee:
CELGENE CORPORATION
Inventors:
Stewart Abbot, Tianjian Li, Bitao Liang
Abstract: Provided are affinity matured and humanized antibodies and antigen-binding fragments thereof that specifically bind to human neuropilin-2 (NRP2) polypeptides, including those that modulate binding interactions between human NRP2 and at least one NRP2 ligand, and which thereby modulate subsequent NRP2-mediated downstream signaling events, including related therapeutic compositions and methods for modulating NRP2 activity and treating diseases such as NRP2-associated diseases.
Type:
Grant
Filed:
October 2, 2020
Date of Patent:
November 7, 2023
Assignee:
aTyr Pharma, Inc.
Inventors:
Luke Burman, Yeeting Chong, Leslie Ann Greene, David King, Zhiwen Xu, Ryan Andrew Adams
Abstract: This document provides methods and materials for assessing a mammal having or suspected of having cancer and/or for treating a mammal having cancer. For example, molecules including one or more antigen-binding domains (e.g., a single-chain variable fragment (scFv)) that can bind to a modified peptide (e.g., a tumor antigen), as well as method for using such molecules, are provided.
Type:
Grant
Filed:
May 16, 2018
Date of Patent:
November 7, 2023
Assignee:
The Johns Hopkins University
Inventors:
Emily Han-Chung Hsiue, Qing Wang, Bert Vogelstein, Kenneth W. Kinzler, Shibin Zhou, Jacqueline Douglass, Michael S. Hwang, Nickolas Papadopoulos
Abstract: The present invention provides an isolated monoclonal antibody that specifically binds human TIM-3. The present invention further provides a pharmaceutical composition comprising the antibody, as well as uses thereof.